高心血管风险HIV患者由增强型PI换用多替拉韦48周对亚临床心血管疾病的影响
NEAT022试验的亚组分析纳入病毒学抑制且高心血管风险的HIV感染者,随机换用多替拉韦或继续增强型PI方案。48周时换药组颈动脉内膜中层厚度进展和脉搏波速度增幅数值上更低,但差异无统计学意义。
要点
- 换用多替拉韦组48周颈动脉内膜中层厚度进展数值低于继续增强型PI组,但差异不显著。
- 换药组脉搏波速度增幅较小,但动脉僵硬度的效应不一致。
- 颈动脉内膜中层厚度趋势在不同Framingham评分、年龄和国家间一致。
核心结论
- 与继续增强型PI相比,高心血管风险且病毒学抑制的HIV感染者换用多替拉韦48周对颈动脉内膜中层厚度进展呈一致有利但无统计学显著性的趋势。
研究设计与样本
- NEAT022为欧洲多中心、开放标签、随机、非劣效性试验。
- 纳入年龄>50岁或Framingham评分>10%且血浆HIV RNA<50 copies/mL持续>24周的成人。
主要发现
- 48周时换用多替拉韦组右侧颈动脉内膜中层厚度平均进展+4 μm,继续增强型PI组+14.6 μm。
- 换药组左侧颈动脉内膜中层厚度平均变化-6.1 μm,继续组+1.6 μm。
- 换药组脉搏波速度平均增加+0.18 m/s,继续组+0.39 m/s,差异均无统计学显著性。
- 颈动脉内膜中层厚度趋势在不同Framingham评分、年龄和国家间一致,动脉僵硬度效应不一致。
临床怎么用
- 对于高心血管风险且病毒学抑制的HIV感染者,由增强型PI换用多替拉韦在亚临床心血管疾病方面未显示显著劣效。
- 颈动脉内膜中层厚度趋势一致有利但需更大样本或更长随访验证。
局限性
- 亚组分析样本量有限,差异未达统计学显著性。
- 动脉僵硬度结果不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Switching from boosted PIs to dolutegravir in virologically suppressed HIV-infected patients with high cardiovascular risk significantly decreased total cholesterol and other proatherogenic lipid fractions at 48 weeks. The impact of this strategy on subclinical cardiovascular disease is unknown. METHODS: NEAT022 is a European, multicentre, open-label, randomized, non-inferiority trial. HIV-infected adults aged >50 years or with a Framingham score >10% were eligible if plasma HIV RNA was <50 copies/mL for >24 weeks on a boosted PI-based regimen. Patients were randomized 1:1 to switch from boosted PIs to dolutegravir or to continue on boosted PIs. Common carotid arteries intima-media thickness (CIMT) and pulse wave velocity (PWV) were measured following a standardized protocol in a subgroup of NEAT022 study participants at baseline and at Week 48. RESULTS: One hundred and fifty-six patients participated in the ultrasonography and arterial stiffness substudies, respectively. In each substudy, population characteristics did not differ between arms and matched those of the main study. At 48 weeks, patients who switched to dolutegravir had lower mean progression of both right (+4 versus +14.6 μm) and left (-6.1 versus +1.6 μm) CIMT and also a smaller increase in mean PWV (+0.18 versus +0.39 m/s) than patients continuing on boosted PIs, although differences were not statistically significant. CIMT trends were consistent across Framingham score, age and country. Inconsistent effects were seen in arterial stiffness. CONCLUSIONS: Relative to continuing on boosted PIs, switching to dolutegravir in virologically suppressed patients with high cardiovascular risk showed consistent favourable although non-significant trends on CIMT progression at 48 weeks.
引用
- Gonzalez-Cordon A, Assoumou L, Camafort M, et al. Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. J Antimicrob Chemother. 2020. PMID: 32737482. doi:10.1093/jac/dkaa292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。